In this photo taken July 6, 2009 worker Roland Ulbrich presents an Aspirin pill made for Italy at the pharmaceutical plant of the Bayer Bitterfeld company in Bitterfeld-Wolfen, eastern Germany. Germany's Bayer AG says it plans to buy U.S. pharmaceutical company Merck & Co. Inc.'s consumer care business, whose products include the Coppertone suncare range, Claritin allergy medicine and the Dr. Scholl's footcare products, for US$ 14.2 billion. (AP Photo/Eckehard Schulz)
In this photo taken July 6, 2009 worker Roland Ulbrich presents an Aspirin pill made for Italy at the pharmaceutical plant of the Bayer Bitterfeld company in Bitterfeld-Wolfen, eastern Germany.  Germany's Bayer AG says it plans to buy U.S. pharmaceutical company Merck & Co. Inc.'s consumer care business, whose products include the Coppertone suncare range, Claritin allergy medicine and the Dr. Scholl's footcare products, for US$ 14.2 billion. (AP Photo/Eckehard Schulz)
In this photo taken July 6, 2009 worker Roland Ulbrich presents an Aspirin pill made for Italy at the pharmaceutical plant of the Bayer Bitterfeld company in Bitterfeld-Wolfen, eastern Germany.  (AP Photo/Eckehard Schulz)

(Irish Times) – A simple aspirin pill can help reduce death rates from cancer by preventing the spread of the disease, new Irish research suggests.

Women who have been prescribed aspirin regularly before being diagnosed with breast cancer are less likely to have cancer that spreads to the lymph nodes than women who were not on prescription aspirin, according to the research funded by the Irish Cancer Society and the Health Research Board.

These women are also less likely to die from their breast cancer, the study of almost 3,000 Irish patients found.

The research, published by the American Association for Cancer Research in the journal, Cancer Research, analyses records from the National Cancer Registry Ireland (NCRI), and prescription data from the General Medical Service (GMS) pharmacy claims database.

READ MORE

Leave a comment

Your email address will not be published. Required fields are marked *